Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benanlofen
- Development stage
- Phase 1
- Lead developer
- Dalian Tianyu Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Benanlofen is a novel non-steroidal anti-inflammatory drug (NSAID) and propionic acid derivative developed by Dalian Tianyu Pharmaceutical. It is designed for the management of acute and chronic pain conditions, including postoperative pain, cancer pain, and renal colic. The drug functions by inhibiting the cyclooxygenase enzymes COX-1 and COX-2, thereby reducing the production of pro-inflammatory prostaglandins. Benanlofen is administered as an injection and has progressed to Phase 2 clinical trials in China for the treatment of postoperative pain, demonstrating its potential as a fast-acting analgesic in clinical settings.
- Other names
- 苯安洛芬
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on benanlofen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on benanlofen.